Din Låsesmed A/S

 

Quicksearch
from your own companies




Analyst: XBRLDenmark
 
Loading...

Loading...

Loading...

Loading...

 
Loading...

Bankruptcy Risk 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/9
Bankruptcy risk for industry  3.2% 3.2% 3.2% 3.2% 3.2%  
Bankruptcy risk  8.4% 8.1% 1.6% 17.8% 2.5%  
Credit score (0-100)  29 29 73 8 62  
Credit rating  BB BB A B BBB  
Credit limit (kDKK)  0.0 0.0 9.7 -0.0 0.0  

How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/9

Net sales  0 0 0 0 0  
Gross profit  9,174 8,470 11,398 5,241 6,785  
EBITDA  360 598 3,263 -2,615 1,795  
EBIT  106 360 3,018 -2,864 1,602  
Pre-tax profit (PTP)  33.5 18.8 2,820.3 -3,016.5 1,420.3  
Net earnings  15.7 12.9 2,181.4 -2,601.5 1,340.0  
Pre-tax profit without non-rec. items  33.5 18.8 2,820 -3,017 1,420  

 
See the entire income statement

Balance sheet (kDKK) 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/9

Tangible assets total  236 232 180 141 134  
Shareholders equity total  416 429 2,610 8.5 1,349  
Interest-bearing liabilities  0.0 0.0 527 1,274 1,912  
Balance sheet total (assets)  6,332 8,684 9,328 8,268 9,087  

Net Debt  -268 -613 222 1,231 1,868  
 
See the entire balance sheet

Volume 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/9

Net sales  0 0 0 0 0  
Net sales growth  0.0% 0.0% 0.0% 0.0% 0.0%  
Gross profit  9,174 8,470 11,398 5,241 6,785  
Gross profit growth  0.0% -7.7% 34.6% -54.0% 29.5%  
Employees  13 16 16 13 11  
Employee growth %  0.0% 23.1% 0.0% -18.8% -15.4%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  6,332 8,684 9,328 8,268 9,087  
Balance sheet change%  0.0% 37.1% 7.4% -11.4% 9.9%  
Added value  360.3 598.2 3,262.9 -2,619.2 1,794.8  
Added value %  0.0% 0.0% 0.0% 0.0% 0.0%  
Investments  658 -415 -470 -461 -329  

Net sales trend  0.0 0.0 0.0 0.0 0.0  
EBIT trend  1.0 2.0 3.0 -1.0 1.0  

Profitability 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/9
EBITDA %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  1.2% 4.3% 26.5% -54.6% 23.6%  
Net Earnings %  0.0% 0.0% 0.0% 0.0% 0.0%  
Profit before depreciation and extraordinary items %  0.0% 0.0% 0.0% 0.0% 0.0%  
Pre tax profit less extraordinaries %  0.0% 0.0% 0.0% 0.0% 0.0%  
ROA %  1.7% 8.7% 34.5% -32.4% 18.5%  
ROI %  26.0% 8.6% 133.6% -129.0% 70.5%  
ROE %  3.8% 3.1% 143.6% -198.7% 197.5%  

Solidity 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/9
Equity ratio %  6.6% 4.9% 28.0% 0.1% 14.8%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net int. bear. debt to EBITDA, %  -74.3% -102.5% 6.8% -47.1% 104.1%  
Gearing %  0.0% 0.0% 20.2% 15,029.2% 141.8%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 0.0% 40.0% 18.4% 11.4%  

Liquidity 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/9
Quick Ratio  0.4 0.6 0.3 0.3 0.3  
Current Ratio  0.9 1.1 1.5 1.1 1.3  
Cash and cash equivalent  267.6 613.4 304.7 43.0 44.3  

Capital use efficiency 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/9
Trade debtors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net working capital  -551.1 454.7 2,925.3 548.6 2,027.5  
Net working capital %  0.0% 0.0% 0.0% 0.0% 0.0%  

Employee efficiency 
2020
2020/12
2021
2021/12
2022
2022/12
2023
2023/12
2024
2024/9
Net sales / employee  0 0 0 0 0  
Added value / employee  28 37 204 -201 163  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  28 37 204 -201 163  
EBIT / employee  8 23 189 -220 146  
Net earnings / employee  1 1 136 -200 122